drugset / Trial / NCT00654498

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

NCT00654498

Phase 3 Completed 306 enrolled Boehringer Ingelheim
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)

Timeline

Start
2008-04
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramipexole Unknown 0.125 mg Oral
Subject Pramipexole Unknown 0.25 mg Oral
Subject Pramipexole Unknown 0.5 mg Oral
Subject Pramipexole Unknown 0.75 mg Oral